about
Randomized, controlled trial of therapy interruption in chronic HIV-1 infectionDried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic TestingTransmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samplesContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyStability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance GenotypingRapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® SystemAn Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 QuasispeciesSimultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assayTime trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational studyMagnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotypingImmunity to HIV-1 is influenced by continued natural exposure to exogenous virus.Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.Genotyping of B and non-B subtypes of human immunodeficiency virus type 1.Cerebrospinal fluid can be used for HIV genotyping when it fails in blood.Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol geneSystematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutationsSurveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand.Differential persistence of transmitted HIV-1 drug resistance mutation classes.High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.Clinical management of HIV drug resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsUse of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisEmergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010.Pharmacogenetics approach to therapeutics.Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays.Towards Better Precision Medicine: PacBio Single-Molecule Long Reads Resolve the Interpretation of HIV Drug Resistant Mutation Profiles at Explicit Quasispecies (Haplotype) Level.Detection of HIV-1 minority variants containing the K103N drug-resistance mutation using a simple method to amplify RNA targets (SMART).Web resources for HIV type 1 genotypic-resistance test interpretation.Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system.Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
P2860
Q24809608-C3116F1B-3B42-46E1-9AE7-DA4E5E7FFC5FQ27488389-2D44966B-705E-45AD-99F7-2509F7E4B52FQ28476489-905EE58B-1744-416C-8410-AC953BEFC9C1Q28539725-B94D27D7-4AEF-4A69-8339-9E8A2CF26EF0Q28541754-8AFEC035-B695-4E3E-9C13-0A57A543AA38Q28546274-0DDC8FCF-BB2F-438D-B1DC-A0CCCD87FA7AQ28551441-1562470B-5E77-4256-A223-C4160DD81949Q28554999-CF705E2F-54A0-4E98-8697-C454A0152C5BQ28660673-AAFB1388-DD0D-459E-94B6-BA6E5D84BCB7Q28728325-5241DB5F-B112-4B81-9503-519DCE92B280Q33264429-869B7CFE-8502-42AC-9EA4-D0ABC10F6CE8Q33379075-0AF22B70-03B2-43A2-8E84-7E33FFB59358Q33565727-13EDDC9B-0862-4934-9C97-6F5AE46229BAQ33622927-BD410A06-A3D3-40AB-956A-9EFC76AE6B60Q33664179-CD68D254-509B-409F-B7DD-4BA34ABCA38CQ33672541-2FD5A6F2-FC76-4BF3-BAAE-00FFCF54A001Q34042412-7B8E304F-DE06-4699-99DA-8C9A38F66229Q34070231-B28788D4-4000-418A-B650-899E6E19FD3EQ34081115-D7416FE6-6C24-46D2-83F8-72F860116528Q34118276-08D998B1-F316-4C23-B3C6-85265BE6021EQ34331628-9AA4F00C-387E-4C96-87E0-22976911BFD5Q34346783-A6015434-C6B1-4C49-8867-CB9EE5E031C2Q35022802-F25B4DC7-A2E4-416C-A0A5-8126E6583BA3Q35066913-F7EB6F28-7EE6-4B1F-81E3-EE8527A898DEQ35261045-28B936ED-7847-4F4F-B5FE-CCB19133CF2FQ35300021-E769DDA7-130D-49A3-9618-10E2B338EB3DQ35636029-6CBE74BF-1934-4FD1-B06C-B47392870426Q35690523-31397B30-276F-47BA-B9C8-F2440FEDD74CQ35887051-A53C2DC7-2EFC-4AD1-BF99-062954067AE0Q35907897-3936ADEB-1EEF-415E-A3CF-2DF8EE0D8AC3Q35917555-47A70C76-4A42-443B-9CB3-37C885910915Q36478845-E9A5B068-A82A-4A22-8031-7D15FDC91680Q36550049-F56BFEDB-00B4-4CEB-8604-499589734972Q36641998-AB00C4B5-D467-412D-9FE8-40C82AAA5B22Q36817632-97AD79F8-EFD0-4E54-B1D4-1E820A36A607Q36899999-AC01B5CB-24D9-42F1-A3D4-373B3EF7696AQ36933330-7BEF3912-65EA-464E-86AF-600D933C3485Q36994525-1FE09F0B-3E0E-4BF1-B622-8696CDD5CF80Q37072022-23F4CA33-F3A6-488C-8E62-87035DCCC571Q37189622-F4F733BA-678A-4215-8713-C7E1664B2928
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Accuracy of the TRUGENE HIV-1 genotyping kit.
@ast
Accuracy of the TRUGENE HIV-1 genotyping kit.
@en
Accuracy of the TRUGENE HIV-1 genotyping kit.
@nl
type
label
Accuracy of the TRUGENE HIV-1 genotyping kit.
@ast
Accuracy of the TRUGENE HIV-1 genotyping kit.
@en
Accuracy of the TRUGENE HIV-1 genotyping kit.
@nl
prefLabel
Accuracy of the TRUGENE HIV-1 genotyping kit.
@ast
Accuracy of the TRUGENE HIV-1 genotyping kit.
@en
Accuracy of the TRUGENE HIV-1 genotyping kit.
@nl
P2093
P2860
P50
P1476
Accuracy of the TRUGENE HIV-1 genotyping kit.
@en
P2093
Caroline Reid
Daniel R Kuritzkes
Dean L Winslow
Gillian F Morgan
John L Sullivan
John W Mellors
Mark Van Gorder
Richard T D'Aquila
Robert M Lloyd Jr
Victoria A Johnson
P2860
P304
P356
10.1128/JCM.41.4.1586-1593.2003
P407
P577
2003-04-01T00:00:00Z